Compare IDEXX Laboratories, Inc. (IDXX) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Petróleo Brasileiro SA — how do they compare? IDEXX Laboratories, Inc. trades at $557.05 (market cap $44.48B), while Petróleo Brasileiro SA trades at $18.4 (market cap $108.78B). The key difference: Petróleo Brasileiro SA is far larger — about 2.4× IDEXX Laboratories, Inc.'s market cap, and Petróleo Brasileiro SA pays a 9.81% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PBR | |
|---|---|---|
Market Cap | $44.48B | $108.78B |
Sector | Health | Technology |
52-Week High | $766.68 | $22.03 |
52-Week Low | $520.87 | $11.54 |
Enterprise Value | $45.38B | $171.32B |
Dividend Yield | — | 9.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Petrobras (PBR) trades at $18.19, up 1.22% with bullish technical indicators and strong fundamentals. The stock shows robust profitability with 21.47% net margins and attractive valuation at 5.73 P/E. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed estimates. The company maintains strong cash flow generation of $197.5B operating cash flow in 2025 and recently announced strategic acquisitions and renewable energy investments.
PBR presents compelling value with deep discount valuation and 50% analyst buy ratings. Key opportunities include production growth initiatives and dividend sustainability, while risks involve commodity price volatility and geopolitical factors in Latin American operations. The stock's current technical strength combined with fundamental undervaluation supports a positive medium-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
